AI assistant
Biotest AG Earnings Release 2019
66_rns_2019-12-04_27474ae3-d49a-4845-af47-3fc3d021e706.html
Earnings Release
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 4 December 2019 15:31
Biotest AG: Biotest AG increases Guidance
Biotest AG / Key word(s): Forecast
Biotest AG: Biotest AG increases Guidance
04-Dec-2019 / 15:31 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Biotest AG increases Guidance
Dreieich, 4 December 2019. Following the evaluation of the current business situation, the Management Board today confirms the revenue guidance for the 2019 financial year in the range of € 420 – 430 million. Although the efforts to find a co-marketing and co-development partner could will not be successfully completed this year, the Management Board increases the guidance for the operating result (EBIT) to € -3 to -13 million, provided that the existing trade conflicts won’t aggravate.
Biotest Aktiengesellschaft
Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: [email protected]
PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
04-Dec-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 – 8 01-0 |
| Fax: | 0 61 03 – 8 01-150 |
| E-mail: | [email protected] |
| Internet: | http://www.biotest.de |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 928425 |
| End of Announcement | DGAP News Service |